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 “A sad soul can kill you quicker, far quicker than a germ.” 
    - John Steinbeck 
 
 
 
 
 
  
ABSTRACT 
Cardiovascular disease and depression are likely to be two of the three leading causes of 
global burden of disease. Depression is common in patients with coronary artery 
disease and is independently associated with increased cardiovascular morbidity and 
mortality. The incidence of major depressive disorder is two to three times higher in 
patients with cardiovascular disease than in the general population. In patients with 
coronary artery disease, clinically significant depression is prevalent in 31% to 45% of 
patients. Moderate to severe depression before coronary artery bypass grafting (CABG) 
is an indicator of worse long-term survival. The overall aim of this thesis was to study 
the association between depression and cardiovascular morbidity and mortality in 
patients undergoing cardiac surgery by epidemiological methods and cross-linking of 
national Swedish registers. 
Study I investigated the association between preoperative antidepressant use and long-
term survival following primary isolated CABG. Of 10884 patients 11% were using 
antidepressants before surgery. After multivariable adjustment, antidepressant use was 
associated with increased mortality hazard ratio (HR) 1.45; 95% confidence interval 
(CI) 1.18–1.77, compared with non-use of antidepressants. Antidepressant use was also 
associated with an increased risk of rehospitalization (HR1.40; 95% CI 1.19–1.65) and 
the composite endpoint rehospitalization or death (HR 1.44; 95% CI 1.26–1.65). 
Study II We hypothesized that depressed patients would have lower use of guideline-
directed medical therapy for secondary prevention of cardiovascular events following 
CABG. We included all 10586 patients who underwent primary isolated CABG in 
Sweden between 2006 and 2008. During the first year after CABG, 93% of all patients 
had at least two dispensed prescriptions for an antiplatelet agent, 68% for an 
ACEI/ARB, 91% for a beta-blocker, and 92% for a statin. 57% had prescriptions for all 
four medication classes. After four years (n=4034), 44% had filled prescriptions for all 
four medication classes. Preoperative depression was not significantly associated with a 
lower use of all four medication classes. 
Study III investigated major depression in 56064 patients who underwent primary, 
isolated, non-emergent CABG. During a mean follow-up of 7.5 years, 114 patients (35%) 
with depression died, compared with 13767 patients (25%) in the control group. 
Depression was significantly associated with increased mortality and the combined end 
point of death or rehospitalization for MI, heart failure, or stroke (multivariable-
adjusted HR 1.65 95% CI 1.37 to 1.99 and 1.61, 1.38 to 1.89, respectively). 
Study IV investigated if socioeconomic factors modified the association between 
preoperative depression and survival following CABG. Antidepressant use was a proxy 
for depression. During a mean follow-up of 4.1 years, 11% patients died in the 
antidepressant group and 9.7% patients died in the control group. The adjusted risk for 
death was higher in patients with preoperative antidepressant use (HR 1.27; 95% CI 
1.13–1.43), and was practically unchanged after the addition of educational level, family 
disposable income, and civil status (HR 1.25; 95% CI 1.11–1.41). 
Study V was a systematic review and meta-analysis performed to provide a summary 
estimate of the association between preoperative depression and long-term survival 
after CABG. Seven studies were included with a combined study population of 89490 
patients (4002 depressed/85488 non-depressed). All studies observed a positive 
association between preoperative depression and all-cause mortality, and in 4 studies 
the association was statistically significant. Patients with depression had a pooled HR of 
1.46 (95% CI: 1.23-1.73, p<0.001) for all-cause mortality with moderate heterogeneity 
(I2 = 50.1% p=0.061). 
In conclusion depression is a significant, independent risk factor, in patients with 
cardiovascular disease and should be considered as important as other well-known risk 
factors like for example heart failure and chronic kidney disease in patients undergoing 
CABG. 
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INTRODUCTION 
Cardiovascular disease (CVD) is the most common cause of death within men and 
women in Sweden today. In 2013, 37% of all deaths were attributable to CVD.1 Acute 
cardiovascular disease is also the most common reason for hospital admission and 
represents 16% of all hospitalizations. Every year approximately 60000 patients are 
cared for in Swedish hospitals due to acute coronary disease to a cost of two billion 
Swedish crowns.2 
Major depression disorder (MDD) is a severe and potentially incapacitating psychiatric 
illness described by a significant change in mood. MDD often has a recurrent or chronic 
course of illness and can end in substantial individual suffering and disability.3 The 
lifetime incidence in the US is predicted to be 12% in men and 20% in women.4 The 
three leading causes of burden of disease in 2030 are foreseen to include HIV/AIDS, 
unipolar depressive disorders, and ischemic heart disease.5 
The aim of this thesis was to study the association between depression and 
cardiovascular morbidity and mortality in patients undergoing cardiac surgery by 
epidemiological methods and cross-linking of national Swedish registers. 
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BACKGROUND 
Myocardial infarction 
Myocardial infarction (MI) is a major cause of death and disability worldwide and may 
be the first manifestation of coronary artery disease (CAD). In patients with established 
disease the disease may occur repeatedly.6 If standardized incident data is collected on 
MI useful information regarding the burden of CAD within and across populations can 
be provided.6 
Myocardial infarction happens when the blood flow that transports oxygen to the heart 
muscle is severely reduced or stopped. This is due to atherosclerosis of the coronary 
arteries. The coronary arteries supply the heart with blood but can slowly become 
thicker and harder from build-up of fat, cholesterol and other substances that together 
are called plaque. This process is called atherosclerosis.7 If there is an atherosclerotic 
plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal 
thrombus in one or more of the coronary arteries, this will lead to decreased myocardial 
blood flow or distal platelet emboli with ensuing myocyte necrosis.6 
There are nine risk factors significantly associated with acute MI: abnormal lipids, 
smoking, diabetes, hypertension, high risk diet, physical inactivity, alcohol use, 
abdominal obesity and psychosocial stress.8 Anand et al. found that women experience 
their first MI approximately 9 years later than men. Higher levels of risk factors 
including abnormal lipids, and smoking, before the age of 60 years largely explain this 
earlier onset among men.8  
Coronary artery bypass grafting 
For patients 40 years and over, CAD represent almost 50% of all hospital admissions in 
Europe and the USA. When medical treatment and percutaneous coronary intervention 
(PCI) do not reduce symptoms and improve the patient´s health in a satisfying way 
coronary artery bypass grafting (CABG) has proven to be an effective treatment for 
ischemic heart disease.9 CABG is an open heart surgical procedure where one or more of 
the coronary arteries are bypassed.9 The first successful human CABG was performed in 
the United States by Dr Goetz and Dr Rothman in 1960.10 
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After pioneering work at the Cleveland Clinics in 1967 CABG evolved over time to be a 
common surgical procedure.11 The main indication for CABG surgery is to relieve 
angina, reduce the likelihood of future or new MIs, to prolong life-expectancy and to 
improve health status and quality of life.12  
In Sweden 5787 open heart surgical procedures were performed in 2015, of these 2623 
were isolated CABG.13 During the 1990s approximately 6500 CABG procedures were 
performed yearly. The reason for this decrease in CABG volumes is the introduction of 
PCI.1 
Depression 
In a study14 about depression, anxiety and their comorbidities in the Swedish general 
population, it was shown that 17.2% of all persons, at any given time point, were 
experiencing clinically significant depression that was likely to affect their daily lives. 
Approximately 5.2% experienced a current major depressive episode. Depression was 
more common among women than men. Co-existence of depression and anxiety 
increased symptom severity and affected health-related quality of life negatively.14  
Symptoms of major depression is depressed mood or loss of interest in almost all 
activities for ≥ 2 weeks, together with three or more of the following symptoms: 
insomnia, feelings of worthlessness, excessive guilt, loss of energy, inability to 
concentrate, change in appetite or weight, and recurrent thoughts of death or suicide.15. 
For major depression suicidal ideation is a fundamental symptom.16 Premature deaths 
in people with depression may be related to physical morbidity as well as death from 
unnatural causes such as suicide.17,18 In Sweden 3 deaths per day are due to suicide.19 
Depression related to coronary artery disease 
In 1993 Frasure-Smith et al. published a study20 demonstrating that patients who were 
depressed at the time of an acute MI had markedly increased mortality compared with 
patients who were not depressed.20 Since then many studies21-23 have investigated the 
relationship between depression and cardiovascular disease and provided evidence 
that depression is prevalent in 20% to 35% in populations with cardiovascular disease. 
Depression seems to be a predictor of cardiovascular disease, and of adverse outcomes 
among patients who already have cardiac disease.23,24 
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Reese et al.25 assessed 766 patients in an Enhancing Recovery and Coronary Heart 
Disease ancillary. The patients were classified using the Diagnostic and Statistical 
Manual for Mental Disorders, Fourth Edition (DSM-IV), as having no depression, minor 
depression and major depression after acute MI. The participants were followed for 
rehospitalizations for up to 24 months. The result revealed that patients with 
depressive disorders had an increased risk of rehospitalization after acute MI. 
Depressed patients had a higher total number of all-cause hospitalizations and visits to 
the emergency department during the 42 months after the initial MI. Patients suffering 
from depression additionally spent significantly more days in the hospital.25 
In patients undergoing CABG, 20-25% suffer from depression.21,23 Depression is a 
strong and independent risk factor for mortality, readmission and cardiac events after 
CABG surgery.21 It can be challenging to detect depression in cardiac patients as some of 
the symptoms such as fatigue and poor appetite are the same as symptoms of other 
medical illnesses.25  
Depressed patients also have the feeling of a poor quality of life and poor physical 
functioning.21 The rate of major depressive disorder is 2- to 3-fold higher in patients 
with CVD than among the general population. Among patients suffering from CVD, 
depression seems to be chronic and recurrent. Studies have shown that for many 
patients, depression has been existing for months or years before a cardiac event rather 
than being a reaction to the event.21 
Studies have also showed that between 21% and 33% of patients who survive an index 
hospitalization for acute coronary syndrome are rehospitalized within one year.25 
Besides high costs for society, hospital readmissions also have an impact on quality of 
life and for younger patients readmissions can adventure economy and employment. 
Therefore it is important to identify factors among patients with coronary disease that 
are associated with increased risk of rehospitalization.25  
Female sex, younger age, lower education level, living alone, suffering from dyspnea and 
previous MI are variables strongly associated with preoperative depressive risk in 
patients undergoing CABG.26 
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Depression related to gender and CABG 
Depression is far more common among women than men. The prevalence ratios 
female:male is around 2:1.27 
It has been shown that women experience more and stronger depressive symptoms 
than men prior to CABG but that the depressive symptoms are at a comparable level 
after CABG.28 Mitchell et al.28 found that women with depression were significantly less 
likely to be married compared to men, less likely to have a paid job and more prone to 
unstable angina than men 28. After surgery there was a trend for men to be sent to 
cardiac rehabilitation programs more often than women. Women experienced more 
physical recovery-related symptoms than men but reported higher levels of social 
support. Women were significantly more depressed and had more severe depressions 
compared to men before CABG but after surgery women´s symptoms were substantially 
improved whilst men´s symptoms improved only slightly.  
Assessment of depression 
More than 50% of patients with mental disorders, and depressive disorders are treated 
in primary care settings.29 Less than half of the patients who are affected are accurately 
diagnosed. This is in part due to biases found in self-reporting screening tools used to 
detect depression. A patient’s culture, gender or somatic symptoms can hinder the 
detection of depression.29 The Beck Depression Inventory (BDI) is the most extensively 
used self reporting tool worldwide. It was developed in 1961, and was designed to 
assess the intensity of symptoms associated with psychoanalytic aspects of depression, 
such as sadness, feelings of failure, guilt, suicidal ideas, and social withdrawal.30 The BDI 
has been criticized for being sensitive to semantically different translations of 
depression screening questions between countries and languages. This may decrease 
the specificity of scores and increase false-positive identifications of the presence of 
depression. It is important to remember that scores from depression screening tools 
cannot form a basis for diagnosis on its own.  
Several studies have shown that clinical depression is a risk factor for cardiac events 
after CABG.31-33 In these studies depression has been defined in different ways. Some 
investigators used self-assessment to define depression and some used anti-depressant 
use as a proxy for depression. The study of Blumenthal et al.31 assessed depression the 
day before surgery according to the 20-item Center for Epidemiological Studies 
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Depression (CES-D) questionnaire (non-depressed (CES-D <16), mildly depressed (CES-
D 16–26), and moderate to severely depressed (CES-D >27). Connerney et al.32 used 
Diagnostic Interview Schedule (DIS) for MDD.32 Tully et al.33 used a 42-item self report 
instrument designed to measure the three related negative emotional states of 
depression, anxiety and tension/stress (DASS).33 In a study by Xiong et al. 34 SSRI use 
was used as a proxy for depression.34. The different ways of assessing depression in the 
studies might affect their results and generalizability. 
Behavioral factors – life style factors 
There are a number of behavioral and lifestyle factors that are involved in the 
relationship between cardiac disease and depression. Patients suffering from 
depression are less likely to engage in health-promoting behaviors like keeping a 
healthy diet, regular exercise, adherence to medications and attendance in cardiac 
rehabilitation programs.21 Depression has also been associated with increased 
smoking35 use of illicit drugs and alcohol use31. However, controversy remains, whether 
it is depression that worsens outcome in patients with cardiovascular disorders or if the 
worse outcome is due to changes in lifestyle and behavior associated with depression. 
Pathophysiology 
There are numerous biological factors in patients suffering from depression that are 
associated with an increased risk of CVD.  
Stress 
One possible hypothesis is related to emotional stress. Stress has been shown to be a 
potent trigger or inducer of depression.36 Stress activates the hypothalamic-pituitary-
adrenocortical (HPA) axis and the sympathetic-adrenomedullary (SA) system. When 
stress is removed, these 2 systems should return to their basal states. But due to genetic 
predisposition, such as specific serotonin transporter gene polymorphisms, coupled 
with gene-environment interaction some individuals may recover from life stressors 
and others may not and later develop depression.37 Depressed patients are in a constant 
state of perceived stress, with continuous upregulation of the HPA axis and the SA 
system. It has been shown in animal models that stress triggers serotonin dysregulation 
which leads to decreased brain monoaminergic activity and the state of depression.38,39 
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Inflammation 
Chronic inflammation has been demonstrated to play a key role in the pathogenesis of 
several chronic disorders including CVD. Noxious stimuli such as cigarette smoke, low-
density lipoprotein cholesterol and hypertension damage the arterial wall and causes a 
state of subacute inflammatory condition.40. Important for arterial repair is activation of 
the platelet clotting cascade.41 With increasing age repair competent cells are not 
always available, artery repair fails and the inflammatory state increases.42  
The most reliable biomarkers of increased inflammation in patients with depression are 
inflammatory cytokines interleukin-6 and tumor necrosis factor (TNF), as well as the 
acute-phase reactant C-reactive protein (CRP).43,44 
CRP is a biomarker of inflammation and several studies have shown elevated 
concentrations in patients suffering from depression.45,46 This inflammatory state might 
play a major role in explaining the increased risk of CAD in patients suffering from 
depression, although the literature is somewhat inconsistent. Bankier et al.47 studied 72 
patients with CAD of whom 30 were diagnosed as having MDD. They found a significant 
association between MDD and CRP levels.47 In a much larger study by Lesperance et 
al.48 plasma levels of soluble intercellular adhesion molecule 1 (sICAM-1) and 
interleukin-6 (IL-6) and the serum level of CRP were measured in 481 patients 2 
months after hospitalization for acute coronary syndromes. Depression was measured 
using the Structured Clinical Interview for DSM-IV. Depressed patients were diagnosed 
with higher levels of sICAM-1, but there was no association with IL-6.48. Frasure-Smith 
et al. used Beck Depression Inventory – II (BDI-II) to define depression and found that 
patients with elevated depression symptoms had higher levels of CRP, but not IL-6, as 
compared with non-depressed cardiac patients.49,50  
However, there are other studies not supporting this observation. In a case-control 
study of depressed (n=57) and non-depressed (n=46) patients with MI there was no 
difference between the groups in levels of IL-6, TNF-α or CRP.51 
Endothelial dysfunction and oxidative stress 
Endothelial dysfunction has been hypothesized to mediate the increased risk of CAD in 
patients with depression.52-54  
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A weakness of previous studies is that they have primarily focused on adults who were 
50 years and older, and it is reasonable to believe that underlying atherosclerosis may 
be contributing to these effects, as it is known to alter mental state as well as 
compromise vascular function.55 This hypothesis was supported by Thomfohr et al.56 
who investigated a sample of healthy, active young women, and found that, symptoms 
of depression were associated with diminished nitric-oxide-mediated vasodilation, 
which is a reflection of endothelial dysfunction.56  
Heart-rate variability 
Reductions in the hearts ability to respond to physiological demand are associated with 
growing risk of cardiovascular disorders and sudden cardiac death.57 Heart-rate 
variability is reduced in patients suffering from depression and could be an explanation 
to increased mortality in patients with depression.58 
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AIMS OF THE THESIS 
 
The overall aim of this thesis was to study the relationship between depression, 
cardiovascular disease and mortality, in patients who undergo coronary artery bypass 
grafting using epidemiological methods and cross-linking of national registers. 
The specific aims were: 
 To study the association between preoperative antidepressant use and survival 
following CABG (Study I) 
 To analyze the association between preoperative depression and guide-line 
directed medications after CABG (Study II) 
 To study the association between preoperative depression and long-term 
survival following primary isolated CABG (Study III) 
 To study the importance of socio-economic status for long-term survival after 
CABG in patients with depression (Study IV) 
 To analyze long-term survival after CABG in patients with depression through 
systematic review and meta-analysis of cohort studies (Study V) 
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PATIENTS AND METHODS 
Registers 
SWEDEHEART 
The Swedish Web system for Enhancement and Development of Evidence-based care in 
Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)2,59 is a 
national registry including all patients who underwent coronary angiography, PCI, or 
cardiac surgery or were cared for at any cardiac intensive care unit in Sweden.2 
Agreement between information in the register and the medical records is described to 
be between 93% and 97%. SWEDEHEART aims to improve patient care by making it 
possible for hospitals to compare results and to provide basis for research. All hospitals 
treating patients with CAD report to SWEDEHEART on a yearly basis. SWEDEHEART 
include five different registers: RIKS-HIA – the register of information and knowledge 
about Swedish Heart Intensive Care Admissions, SEPHIA – Secondary prevention after 
Heart Intensive Care Admission, SCAAR – Swedish Coronary Angiography and 
Angioplasty Registry, Swedish Heart Surgery Registry – started in 1992 and covers 
100% of all cardiac operations performed in all eight hospitals performing cardiac 
surgery in Sweden. 
The Swedish National Patient Register 
In 1964 the Swedish National Board of Health and Welfare started the National Patient 
Register (NPR).60 The NPR covers all diagnoses for all patients hospitalized in Sweden 
since 1987. It covers more than 99% of all somatic and psychiatric hospital discharges 
including patient data, geographical data, administrative data of the hospital stay, and 
medical data. Discharge codes used in the NPR are based on the International 
Classification of Diseases (ICD). The validity of the register has frequently shown to be 
high, with a 95% validity for a primary diagnosis of heart failure, 98.6% for stroke and 
98 to 100% for MI.60,61 
The Cause of Death Register 
Under the supervision of the Swedish National Board of Health and Welfare the Cause of 
Death Register was started in 1952. The registry contains data of all deceased persons 
registered in Sweden since 1961, regardless if the person died in Sweden or abroad. 
Information about cause of death and date of death can be obtained from the registry. 
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The diagnoses are coded according to the ICD and since 1997 causes of death are 
classified according to the international version of ICD-10. About 1-2 % of registered 
deaths have missing cause of death and are coded as without known cause of death.62  
Total Population Register 
The Total Population Register is a national register maintained by Statistics Sweden. 
The registry covers all people registered in Sweden since 1968 and is updated 
continuously. The registry contains information regarding name, place of birth and 
residence, sex, age, civil status, citizenship, immigration and relationships such as 
married couples and child-parent. Hundred percent of all deaths are reported to 
Statistics Sweden within one month.63 
The Prescribed Drug Register  
The Prescribed Drug Register, maintained by the Swedish National Board of Health and 
Welfare, contains information on dispensed prescriptions in all out-patient care 
covering the entire population of Sweden since July 2005. The register includes the 
ATC-code and the date of dispensing.64 
Longitudinal integration database for health insurance and labor market studies (LISA)  
The LISA register is a national register maintained by Statistics Sweden that holds 
annual registers since 1990 and includes all individuals above 16 years of age. The 
database provides information about employment, income, country of birth and place of 
residency, parental countries of birth and educational status. The primary objective in 
LISA is the individual, but connections to family, companies and places of employment 
are also available.65 
The Swedish Personal Identification Number 
Since 1947 all Swedish citizens have a unique personal identity number. It consists of 
the date of birth, a three-digit birth number and a check digit. When an individual reside 
in Sweden on a permanent basis, and is recorded in the Total population register, he or 
she is assigned a personal identity number. The unique personal identity number is of 
great importance in Swedish health care as well as in medical research. It facilitates 
linkage between registers and makes large-scale medical register-based research 
possible.66  
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Overview of study design and methods in Study I-IV 
 Study I Study II Study III Study IV 
Design Nationwide population-based cohort study 
Data source 
The SWEDEHEART register 
The National Patient Register 
The Prescribed Drug Register 
Cause of Death register 
LISA in addition 
to registers 
used in Study I-
III 
Cohort Adults undergoing primary isolated CABG in Sweden 
Period 2006 to 2008 2006 to 2013 
Follow-up 
Until Feb, 2011 for 
survival. 
Until Dec 31, 2009 
for AMI. Until Dec 
31, 2008 for heart 
failure and stroke 
Until one year 
after surgery. 
Until Feb, 2011 
for survival. 
Until Dec 31, 
2009 for AMI. 
Until Dec 31, 
2008 for heart 
failure and stroke 
Until Mar, 2014 
for survival 
Exposure Antidepressant use 
Diagnosis of 
depression in the 
National Patient 
Register 
Antidepressant 
use 
Outcome 
Primary: All-cause 
mortality 
Secondary: 
rehospitalization 
for AMI, heart-
failure or stroke, 
and a composite 
endpoint of all-
cause mortality or 
rehospitalization 
At least 2 
dispensed 
prescriptions <1 
year after CABG 
in all 4 
medication 
classes: 
antiplatelet 
agents, ACEI, 
beta-blockers, 
statins 
Primary: All-cause 
mortality 
Secondary: a 
combination of 
all-cause 
mortality and 
rehospitalization 
for AMI, heart 
failure or stroke 
All-cause 
mortality 
Statistical 
method 
Multivariable 
survival analysis 
(Cox regression) 
Modified 
Poisson 
regression 
Multivariable survival analysis 
(Cox regression) 
Confounders 
Age, sex, diabetes 
mellitus, COPD, 
LVEF, acute 
kidney injury, 
postoperative 
antidepressant 
use 
Age, sex, 
smoking, atrial 
fibrillation, 
diabetes, 
hyperlipidemia, 
hypertension, 
COPD, PVD, AMI, 
stroke, LVEF, 
heart failure 
Age, sex, renal 
function, LVEF, 
diabetes, COPD, 
PVD, acute kidney 
injury, stroke, 
heart failure 
Age, sex, 
cardiovascular 
risk factors, 
marital status, 
income. 
education, 
region of birth 
ACEI = angiotensin converting enzyme inhibitors, AMI = acute myocardial infarction, COPD =  
chronic obstructive pulmonary disease, LISA = the longitudinal integration database for health 
insurance and labor market studies, LVEF = left ventricular ejection fraction, PVD =  
peripheral vascular disease 
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Ethics 
All studies were approved by the regional Human Research Ethics Committee in 
Stockholm, Sweden. 
Data collection 
Study I-III 
The Swedish National Board of Health and Welfare used the unique Swedish personal 
identity number to link information regarding CABG patients from 1995-2008 from the 
SWEDEHEART register with the National Patient Register, The Prescribed Drug 
Register and the Cause of Death register with follow-up until February 2011. 
Information about baseline patient characteristics was extracted from SWEDEHEART, 
and from the Swedish National Patient Register (Swedish National Board of Health and 
Welfare).  
Study IV 
In this study, the data extraction procedure was repeated using the same registers as in 
Study I-III and additionally, data linking was performed using The Longitudinal 
integration database for health insurance and labor market studies (LISA) managed by 
Statistics Sweden, to obtain information about socioeconomic status. Again, the Swedish 
National Board of Health and Welfare used the Swedish personal identity number to 
link information regarding patients who underwent cardiac surgery from the 
SWEDEHEART register, and now with inclusion time until 2013 and follow up until 
March 2014.  
Study population 
Study I 
From the SWEDEHEART register, we identified 14032 patients who underwent CABG 
between January 2006 and December 2008. We excluded 227 patients who had 
previous cardiac surgery, and 2261 patients who had another cardiac procedure in 
addition to CABG. Finally, we excluded 660 patients who underwent emergency surgery 
defined as surgery within 24 hours of decision. The final study population consisted of 
10884 patients who underwent primary isolated non-emergent CABG, of these patients 
1171 had a dispensed prescription of antidepressants before they underwent CABG.  
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Study II 
From the SWEDEHEART registry 14032 patients who underwent CABG between 
January 2006 and December 2008 were identified. We excluded 227 patients who had 
previous heart surgery, 2261 patients who had another cardiac procedure than isolated 
CABG, 660 patients who were operated within 24 h from decision, and 298 patients 
who had a shorter follow-up time than one year. The final study population included 
10586 patients (1132 depressed and 9454 non-depressed) who underwent primary 
isolated non-emergent CABG. 
Study III 
We identified 69243 patients who underwent CABG from 1997 to 2008 from the 
SWEDEHEART register. We excluded 1234 patients who had previous cardiac surgery 
and 9509 patients who had another cardiac procedure in addition to CABG. Finally, we 
excluded 2436 patients who underwent emergency surgery defined as surgery within 
24 hours of decision to operate. The final study population consisted of 56064 patients 
who underwent primary isolated non-emergent CABG. We identified 324 patients with 
a preoperative diagnosis of depression from the National Patient Register. The 
remaining 55740 patients were categorized as the control group 
Study IV 
We included 22930 patients who had undergone primary isolated non-emergent CABG 
between January 2006 and December 2013, from the SWEDEHEART register. Patients 
were excluded if they had undergone previous cardiac surgery or had concomitant 
procedures in addition to CABG or if they underwent surgery within 24 hours of 
decision to operate. Finally, we excluded patients who died within one year of surgery, 
because the outcome of interest was dispensed prescriptions after a minimum of one 
year of follow-up. We identified 3078 (13%) patients who had at least one dispensed 
prescription of antidepressants before they underwent CABG. 
Study V 
Study V was a systematic review and meta-analysis. We included all cohort studies 
investigating the association between depression prior to CABG and long-term survival.  
We excluded all studies that were not cohort studies, and studies focusing on 
postoperative depression. A total of 1357 unique records were recognized through the 
literature search. Of these, 1209 were excluded due to title or abstract content, 80 due 
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to wrong population or outcome and 24 were review articles. The remaining 44 full-text 
articles were assessed for eligibility and 7 studies met the inclusion criteria. Studies 
included in the systematic review and meta-analysis were published between 2003 and 
2015, and included data for 89490 patients from the USA, Sweden and Australia. 
Preoperative depression was existing in 4215 patients. The number of patients in each 
study ranged from 309 to 56064 with median or mean follow-up ranging from 3 to 9.3 
years. 
Definition of depression 
In study I, II and IV we used antidepressant use as a proxy for depression. We used the 
national Prescribed Drug Register (Anatomical Therapeutic Chemical (ATC) code N06A, 
except for the following substances: N06AX02 and N06AX12). Preoperative 
antidepressant use was defined as having had at least one dispensed antidepressant 
prescription before the date of surgery. 
In study III we used the National Patient Register to identify patients with a diagnosis of 
depression ICD-10 code: F3 and ICD-9 codes: 296, 311, 300.4, 309.0, and 309.1. 
Outcome measures 
All-cause mortality was the primary end-point in study I, III and IV. Information about 
death was obtained from the national Total Population Register. The primary outcome 
measure in study II was medication use defined as at least two dispensed prescriptions 
with the following ATC-codes: B01AC (antiplatelet agents), C09 (ACEI/angiotensin 
receptor blockers (ARB)), C07 (beta-blockers), and C10AA (statins) from the national 
Prescribed Drug Register after at least one year of follow-up, and at least four years of 
follow-up, respectively. 
In study I, secondary outcome measures were rehospitalization for MI, heart failure or 
stroke, and a composite endpoint of all-cause mortality or rehospitalization for MI, 
heart failure or stroke. 
In study III, the secondary outcome measure was a combined end-point of all-cause 
mortality or rehospitalization for MI, heart failure or stroke. 
Statistical analysis 
Study I 
Baseline characteristics were described using means and standard deviations for 
continuous variables, and frequencies and percentages for categorical variables. The 
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Kaplan–Meier method was used to calculate cumulative survival and construct survival 
curves for the exposed and unexposed group, and the log-rank test to compare 
differences between the curves. We used Cox proportional hazards regression with and 
without multivariable adjustment to model survival. In a further effort to reduce 
selection bias, propensity score methods for stratification and regression adjustment 
was used. Stata version 12.1 (StataCorp LP, College Station, TX, USA.) was used for all 
analyses 
Study II 
To describe baseline characteristics means and standard deviations were used for 
continuous variables and frequencies and percentages for categorical variables. We 
used modified Poisson regression with a robust estimator of variance to calculate risk 
ratios (RR) for the use of each medication class for depressed patients with non-
depressed patients as reference category. We reported unadjusted and multivariable 
adjusted RR with 95% CI. We also analyzed the distribution of medication class and 
medication use in men and women separately. Finally, we investigated the time trend in 
secondary prevention medication by comparing the distribution of medication class for 
patients who underwent surgery in 2006 to that of patients who underwent surgery 
during 2008. Stata version 13.0 (StataCorp LP, College Station, TX) was used for all data 
management and statistical analysis. 
Study III 
The Kaplan-Meier method was used to calculate cumulative survival and construct 
survival curves for the exposed and unexposed group and the log-rank test to compare 
differences between the curves. We used Cox proportional hazards regression to model 
survival. We created several multivariate models considering all baseline 
characteristics. Stata, version 12.1 (StataCorp LP, College Station, Texas), was used for 
all analyses. 
Study IV 
Baseline characteristics were described with frequencies and percentages for 
categorical variables and means and standard deviations for continuous variables. The 
crude incidence rates and 95% confidence intervals (CIs) were calculated and the 
Kaplan−Meier method was used to calculate cumulative survival. We used Cox 
proportional hazards regression with and without multivariable adjustment to model 
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survival. Age and body mass index were modeled as restricted cubic splines, and all 
other variables were included as categorical terms. We calculated propensity scores for 
each patient by logistic regression, with antidepressant use as the dependent variable 
and all baseline characteristics as independent variables. The propensity scores were 
first used for regression adjustment and were included in the multivariable Cox 
regression model as a continuous variable, and then divided into quintiles and a 
separate Cox regression model was stratified by propensity score quintile. We also 
constructed a 1:1 propensity score-matched cohort by nearest neighbor matching 
without replacement, and a caliper width equal to 0.2 of the SD of the logit of the 
propensity score. Standardized differences for variables were calculated to investigate 
post-match balance. Data management and statistical analyses were performed using 
Stata 13.1 (Stata Corp LP, College Station, TX,USA) and R version 3.1.3 (R Foundation for 
Statistical Computing, Vienna, Austria). 
Study V 
Adjusted HR and 95% CI was extracted from the selected articles. Fixed and random 
effects models were used to compute the pooled HR and 95% CI. The random effects 
model was used to take into account the possible clinical diversity and methodological 
variation amongst studies. The random and fixed effect models showed similar results. 
Additional tests included: Q-test to test heterogeneity between trials; I2 to estimate the 
percentage of total variation across studies due to heterogeneity rather than chance. I2 
can be calculated as follows: I2 = 100%*(Q-df)/Q (where Q represents Cochrane´s 
measure of heterogeneity and the degrees of freedom), and can be categorized into low 
(<50%), moderate (51-75%), or high (>75%) according to predefined criteria 67. 
Sources of heterogeneity were further investigated by sensitivity analyses in which the 
pooled estimates were calculated omitting one study at a time using a random effects 
model.  Data management and statistical analyses were performed using R version 3.2.3 
(R Foundation for Statistical Computing, Vienna, Austria). 
Missing data 
Multiple imputation by chained equations was used to handle missing data.68,69 The 
event indicator and the Nelson–Aalen estimator of the cumulative baseline hazard were 
included in the imputation model.70 The objective of imputation was to retain statistical 
power and reduce selection bias that may occur when deleting observations with 
missing covariates.  
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RESULTS 
Study I 
Patient characteristics 
Baseline characteristics of the study population in study I are shown in Table 1. The 
incidence of antidepressant use was 11% in the study population. Patients in the 
exposed group were more likely to be women, smokers and suffer from diabetes 
mellitus. 
Primary outcome measure  
The primary outcome measure was all-cause mortality. During a mean follow-up of 3.5 
years 116 patients (9.9%) died in the exposed group and 765 patients (7.9%) in the 
non-exposed group. In the unadjusted Cox regression analysis, antidepressant use was 
associated with increased mortality (HR 1.36; 95% CI 1.12–1.65), compared with non-
use of antidepressants. In the final multivariable model, antidepressant use was 
associated with increased mortality (HR 1.45; 95% CI 1.18–1.77), compared with non-
use of antidepressants. The final multivariable model included the following covariates: 
age, sex, diabetes mellitus, chronic obstructive pulmonary disease, preoperative left 
ventricular function, acute kidney injury (>0.3 mg/dL (26 μmol/L) increase in 
postoperative creatinine), and postoperative antidepressant use (Table 2 and Figure 1).  
Secondary outcome measures 
Secondary outcome measures included rehospitalization for MI, heart-failure or stroke, 
and a composite endpoint of all-cause mortality or rehospitalization (Table 3). 
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Figure 1 
Overall survival from an unadjusted analysis of 1171 patients who were treated with antidepressants 
compared with 9713 patients with no antidepressant use before primary isolated coronary artery 
bypass surgery. The inset shows the same data on an enlarged y axis. 
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Study II 
Patient characteristics are presented in Table 4. Female sex, current smoking, a history 
of stroke, and diabetes were more common in patients with depression. 
 
Primary outcome measure 
During the first year after CABG, 93% of all non-depressed patients had at least two 
dispensed prescriptions for an antiplatelet agent, 68% for an ACEI/ARB, 91% for a beta-
blocker, and 92% for a statin. Fifty-seven percent of all non-depressed patients had 
prescriptions for all four medication classes. Among depressed patients 94% had at 
least two dispensed prescriptions for an antiplatelet agent, 72% for an ACEI/ARB, 90% 
for a beta-blocker, and 93% for a statin. Fifty-eight percent of all depressed patients had 
prescriptions for all four medication classes. (Figure 2). During the fourth year after 
CABG, compliance was generally lower. Among non-depressed patients, 44% used all 
four medication classes, compared to 46% among depressed patients (Figure 3). 
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Figure 2. Distribution of medication use one year after surgery in 10,586 patients who underwent 
primary isolated CABG between 2006 and 2008 in Sweden. ACEI =angiotensin-converting enzyme 
inhibitor, ARB = angiotensin II receptor blocker, CABG = coronary artery bypass grafting. 
 
 
 
 
Figure. 3. Distribution of medication use four years after surgery in 4034 patients who underwent 
primary isolated CABG between 2006 and 2008 in Sweden. ACEI =angiotensin-converting enzyme 
inhibitor, ARB = angiotensin II receptor blocker, CABG = coronary artery bypass grafting. 
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After multivariable adjustment, there was no significant association between 
depression and all four classes of guideline-directed medical therapy for secondary 
prevention (RR 0.97, 95% CI: 0.86 to 1.09) four years after surgery (Table 5 and 6). 
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Time trends 
Antiplatelet agent and beta-blocker use was similar for patients going through surgery 
in 2006 as compared to those who underwent surgery in 2008. During the same time 
period, a small increase in the use of ACEI/ARB and statins was noted (Figure 4). 
 
 
Figure. 4. Distributions of medication use in patients with or without depression who underwent 
CABG in 2006 compared to 2008. ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin 
II receptor blocker, CABG = coronary artery bypass grafting. 
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Study III 
Baseline characteristics of the study population are listed in Table 7. Patients with 
depression and the control group were not balanced regarding several potentially 
confounding factors, most importantly, female gender, diabetes mellitus, peripheral 
vascular disease, chronic obstructive pulmonary disease, and a history of stroke. 
 
Primary outcome measure 
In the unadjusted Cox regression analysis, depression was associated with increased 
mortality HR 1.94, 95% CI 1.61 to 2.33 (Figure 5). The unadjusted 1-, 5-, and 12-year 
survival was 93%, 80%, and 41% in depressed patients and 97%, 89%, and 63% in the 
control group (p <0.001), respectively. In the final multivariate Cox regression model, 
depression was significantly associated with increased mortality: HR 1.65, 95% CI 1.37 
to 1.99 (Table 8). 
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Secondary outcome measure 
In the unadjusted Cox regression analysis, depression was significantly associated with 
the combined end point: HR 2.01, 95% CI 1.73 to 2.35 (Figure 6). Depression was 
significantly associated with the combined end point in the multivariate-adjusted 
model: HR 1.61, 95% CI 1.38 to 1.89 (Table 9). 
 
 
Figure 5. Kaplan-Meier estimated survival in 56064 patients with or without depression diagnosis 
before primary isolated CABG from 1997 to 2008 in Sweden. 
 
 
 
 
 
Figure 6. Kaplan-Meier estimated freedom from the combined end point of death or 
rehospitalization for myocardial infarction, heart failure, or stroke in 56064 patients with or without 
depression diagnosis before primary isolated CABG from 1997 to 2008 in Sweden. 
 
 
  
 30 
 
 
 
 
 
 
  
  31 
Study IV 
Baseline characteristics are shown in Table 10. Patients with antidepressant use were 
more often women, had a history of alcohol dependency and chronic obstructive 
pulmonary disease, and had a lower family disposable income. 
 
 
 
Primary outcome measure 
In the unadjusted Cox regression analysis, antidepressant use was associated with 
increased mortality (HR 1.33; 95% CI 1.19–1.50), compared with non-use of 
antidepressants (Figure 7).  
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Figure 7. Kaplan-Meier estimated survival in 22930 patients who underwent coronary artery bypass 
surgery in Sweden 2006-2013 according to preoperative antidepressant use. 
 
After multivariable adjustment for cardiovascular risk factors, antidepressant use was 
associated with increased mortality (HR 1.27; 95% CI 1.13–1.43). The addition of SES 
variables educational level, family disposable income, and civil status to the model 
resulted in a very small change in the estimated risk for death: HR 1.25; 95% CI 1.11–
1.41 (Figure 8). 
 
 
Figure 8. Multivariable adjusted hazard ratios and 95% confidence interval for all-cause mortality in 
22930 patients who underwent coronary artery bypass surgery in Sweden 2006-2013.  
  33 
The association between antidepressant use and all-cause mortality was investigated in 
selected subgroups. The increased risk for mortality in patients with preoperative 
antidepressant use was similar in patients younger vs. older than 70 years, men vs. 
women, and in tertiles of family disposable income, levels of education, and civil status 
(Figure 9). 
 
 
Figure 9. Hazard ratios for all-cause mortality in 22930 patients who underwent coronary artery 
bypass surgery in Sweden 2006-2013 according to preoperative antidepressant use in selected 
subgroups. 
  
 34 
Study V 
Characteristics of the included studies are presented in Table 11. Preoperative 
depression was present in 4215 patients. The number of patients in each study ranged 
from 309 to 56064 with median or mean follow-up ranging from 3 to 9.3 years. The 
overall pooled HR for preoperative depression and mortality was 1.46; 95% CI 1.23 to 
1.73, according to a random effects model with moderate heterogeneity (I2 = 50.1% 
p=0.061) (Figure 10). 
 
 
 
Figure 10. Forest plot of preoperative depression and survival following CABG. 
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DISCUSSION 
Methodological considerations 
Epidemiologists study the occurrence of diseases, effects of treatments and compare 
treatments and preventive actions. Important to consider in all epidemiological studies 
are the corner stones: internal validity (systematic errors), precision (random errors), 
causality and external validity (generalizability).71 
Cohort studies 
Epidemiologic study designs can be divided into two main categories: intervention 
(experimental) or observational studies (descriptive or analytic). Study I-IV are analytic 
observational studies. A cohort is a group of individuals being followed over a period of 
time. The archetype of all epidemiologic studies is the cohort study. In a cohort study 
the occurrence of disease is measured within one or more cohorts.71  
Internal validity (systematic errors or bias) 
Bias can be classified into three broad categories: selection bias, information bias and 
confounding.  
Selection bias occurs if the association between exposure and disease is different 
between those who participate in the study and those who do not.71  
Information bias is introduced if the information collected from or about the study 
participants is not collected in a correct way. This kind of information is referred to as 
being misclassified - if it leads to a person being placed in an incorrect category. 
Misclassification of study participants can be divided into differential or non-differential 
misclassification. If the misclassification is different for patients in the exposed and the 
non-exposed group, the misclassification is differential. When the misclassification is 
unrelated to the exposure or disease it is non-differential. Differential misclassification 
is more problematic than non-differential as it can result in under- and overestimation 
of the results.71 
Confounding is often referred to as confusion or mixing of effects. The effect of the 
exposure is mixed up with the effect of another variable and therefore leading to bias. A 
confounder is always associated with both exposure and outcome. A confounder 
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describes an association that is true but might be misleading and leading to incorrect 
interpretation. Confounders can be handled in a study protocol before starting the study 
by randomization, restriction, or matching, or in the statistical analysis by stratifying or 
multivariable statistical models.71 
Random error is the error that remains after systematic error is eliminated or in other 
words, the influence of chance. It is the variation in data that cannot be explained and is 
to some extent present in all studies Larger studies increase precision and reduce 
random error and smaller studies have less precision and therefore higher risk of 
random error.71  
External validity or generalizability is another important concern. That is the ability to 
apply results from one study to other cohorts or settings than where the study was 
conducted.71 
Causality 
Causation means that one thing will cause the other. "Correlation does not imply 
causation" is a phrase often used to emphasize that a correlation between two variables 
does not imply that one causes the other. August Bradford Hill (1897-1991), a British 
medical statistician, outlined the minimal conditions needed to establish a causal 
relationship between two items. He suggested the following set of criteria:72 
Strength – the stronger the association, the more likely is a causal effect. 
Consistency – if a relationship is causal we would expect consistency if the study was 
replicated. 
Specificity – the probability of a causal relationship increases the more specific an 
association between a factor and an effect is. 
Temporality - exposure must always precede the outcome. 
Biologic gradient – refers to the presence of a dose-response relationship. A present 
dose-response relationship gives stronger evidence for causal relationship. 
Plausibility – for causation the relationship should be plausible, in other words, the 
results should be biologically sensible. 
Coherence – the association should be consistent with results from a number of studies. 
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Experimental evidence – if the factor of interest is removed the risk of disease should be 
reduced. 
Analogy – the necessity to consider multiple hypotheses before making conclusions 
about a causal relationship. 
Study I 
We investigated the association between preoperative antidepressant use and survival 
following CABG, and the association between preoperative antidepressant use and 
rehospitalization for MI, heart failure or stroke. Patients who were treated with 
antidepressants before surgery had 45% higher risk for death. The risk for 
rehospitalization, MI, heart failure or stroke was also significantly increased among 
patients with anti-depressant use. The reported incidence of depression among patients 
with CVD varies between 31-45%. In our study only 11% of the patients had a 
dispensed prescription of antidepressants before the date of surgery. This is most likely 
an underestimation of depression and is related to our definition of depression. We 
defined exposure based on whether or not a patient had at least one dispensed 
prescription with antidepressants at any point in time from July 2005, and before the 
date of surgery. To investigate the effect of elapsed time between dispensing of a 
prescription for antidepressants and surgery, we reclassified the exposure first as a 
dispensed prescription within 6 months before surgery, and second, as a dispensed 
prescription within 1 year before surgery. The results from these analyses were 
practically the same as our main analysis. 
A possible explanation to the higher mortality in the exposed group is that the use of 
SSRI inhibits platelet function and therefore increases the risk of bleeding.73 This has 
been investigated in patients undergoing orthopedic surgery. An increased risk of 
bleeding and need for blood transfusion was found in patients who were treated with 
serotonergic antidepressants.74 However, published studies are conflicting. Kim et al.75 
carried out a study in patients who had received any antidepressants before CABG and 
categorized the patients into SSRI users and non-SSRI users before CABG.75 The SSRI 
group comprised of 1076 patients and the non-SSRI group of 304 patients. The study 
showed that SSRI use before CABG was not related to increased risk for bleeding or in-
hospital mortality after CABG. These findings were in line with the results of a Danish 
population-based cohort study conducted by Andreasen et al.76 They studied 
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transfusion requirements among 3454 patients undergoing CABG in Denmark between 
1 January 1998 and 31 December 2003. The aim of the study was to find out if the 
requirement for red blood cell transfusion was increased following preoperative SSRI 
use among these patients.76 Andreasen et al. came to the conclusion that SSRI use before 
CABG did not increase the necessity for red blood cell transfusion.76 Additionally, they 
found no association between antidepressant use and re-exploration for bleeding or 30-
day mortality. These findings were also supported by Tully et al.77 They investigated 
4136 patients who underwent CABG surgery. Of these patients 105 (2.5%) were 
SSRI/SNRI users. SSRI/SNRI users did not experience severe bleeding events or long-
term mortality after CABG surgery.77 
In our study we also performed a separate analysis in patients with at least one 
dispensed prescription with ATC-code N06AB (SSRI) before undergoing primary 
isolated non-emergent CABG. We found that SSRI use was associated with an increased 
risk of the different clinical endpoints (all-cause mortality, rehospitalization or the 
composite endpoint), compared with non-use of SSRIs.  
The results from our study indicate that depression should be considered an important 
risk marker for prognosis following CABG surgery. 
Study II 
Study II was conducted in the same study population as in study I. We investigated if 
patients with depression would have lower use of guideline-directed medications for 
secondary prevention of cardiovascular events following CABG than patients without 
preoperative depression. The purpose was to explore if this could explain the higher 
mortality among patients with depression. Preoperative depression was not associated 
with lower use of guideline-directed medications for secondary prevention of 
cardiovascular events. These findings suggest that the observed higher mortality 
following CABG among depressed patients is not explained by inadequate secondary 
prevention medication. Secondary prevention medications were similar between men 
and women. Previous research has indicated that depressed patients do not receive 
optimal coronary care due to failing in communication and patient cooperation.78 Due 
to this, and our results in study I, we hypothesized that depressed patients could have 
worse secondary prevention medications compared to non-depressed patients. 
However, we did not find a lower use of secondary prevention medications among 
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patients with preoperative depression. Our results differ from the observations by 
Kronish et al.79 They found that persistently depressed patients had a lower adherence 
to secondary prevention medications and behaviors at three months after acute 
coronary syndrome than persistently non-depressed patients. In our study we did not 
evaluate postoperative depressive status, but it has been shown that preoperative 
depression is associated with the highest risk for postoperative depression.80 
Depression is a risk factor for mortality after CABG23,81 and studies have shown that 
improvement of depression symptoms was consistently associated with better 
adherence to medications in patients hospitalized with cardiac conditions.82 This is one 
of the reasons to why it is important to detect and treat depression before CABG, to 
increase the likelihood of adequate adherence to secondary prevention medications. 
Study III 
In study III we wanted to study the relation of major depression to survival after CABG. 
We acquired information regarding depression diagnosis from the National Patient 
Register. In this way we were able to capture the most severely ill patients because 
these patients were treated in a hospital or by a psychiatrist in the specialized 
outpatient clinic because of their depression. 
We identified 324 patients with a preoperative diagnosis of depression. During a mean 
follow-up of 7.5 years we found a significant association between preoperative 
depression and long-term survival after CABG. Preoperative depression was also 
associated with an increased risk of the combined endpoint of death or 
rehospitalization for heart failure, MI or stroke. The observed association between 
depression and mortality differed between men and women. Although depression was 
more common in women, the association between depression and long-term mortality 
was statistically significant only in men and not in women. This may in part be 
explained by the fewer number of female patients in the study or other mechanisms 
that we were unable to identify. One possible mechanism to why more women than 
men suffer from depression could be that depression can take different shapes in men 
and women.83 Symptoms of anger, irritability, risk-taking behaviors, and substance 
abuse are more likely to be reported among men with depression over more traditional 
symptoms such as sleep problems and withdrawal from social occasions.83 If only 
traditional symptoms are taken into account in clinical care, depression could be 
underdiagnosed in men.83 
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The findings in our study are supported by another Swedish study.84 Gale et al.84 
investigated the association between different mental disorders in 1107524 Swedish 
young men at conscription and the risk of incident CAD. The age-adjusted HR regarding 
depression at conscription and incident CAD was 1.30 (95% CI 1.05 to1.60). As the 
participants in this study were young, it is unlikely that the association between 
depression and incident CAD was due to reverse causation, that is, living with 
cardiovascular disease causes depression. 
Behavioral factors should be taken into account concerning postoperative morbidity 
events in patients on antidepressant medication. Depressed persons have a tendency to 
smoke35, drink85 and use illicit drugs to a larger extent than persons without 
depression. In our study there were more smokers in the group taking antidepressants 
before the operation compared to the unexposed group, which are in line with earlier 
findings regarding depression and smoking. A concern is that it was difficult to get 
reliable and correct information regarding smoking. We may have information bias 
regarding smoking in our study. However, we have information regarding chronic 
obstructive pulmonary disease which could be used as a proxy for smoking. Depressed 
persons are reportedly less physically active86, have poorer diets, care less about 
hygiene and self-care, and are less likely to take prescribed medicine according to 
schedule.87 
Study IV 
A limitation in our earlier studies was the lack of information regarding socioeconomic 
status (SES). It is possible that SES could have an effect on the relationship between 
depression and prognosis. In this study we retrieved information regarding SES 
(marital status, education, income, region of birth). The emphasis of this study was to 
investigate the effect of socioeconomic factors and how these factors modify the 
association between depression and survival after CABG. We used the same exposure as 
in study I, antidepressant use. We found that among patients who underwent CABG in 
Sweden, preoperative antidepressant use was associated with worse survival even after 
controlling for socioeconomic factors. Little is known about the effect of SES in patients 
with preoperative depression and survival after CABG. In a study by Poole et al.88 length 
of hospital stay in patients with preoperative depression undergoing CABG and the role 
of SES was investigated. They used yearly household income as a proxy for SES, and 
grouped the patients into five categories according to SES. A dose-response relationship 
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between depression symptoms and length of hospital stay was found, and they also 
found an interaction between depression symptoms and household income. The 
negative effect of depression was augmented by a low income while a higher income 
reduced the negative effect of depression on length of stay.88 In a large Danish cohort 
study including 56581 patients between 2003 and 2012 the relationship between 
socioeconomic position and survival after stroke was investigated.89 The authors 
discovered that lower income was significantly associated with worse survival after a 
stroke, while level of education was less important for prognosis, especially in patients 
older than 65 years.89 Like in our study, socioeconomic position was measured as 
household income and length of education. 
Lower SES has been linked to poorer health and shorter life expectancy compared with 
persons with higher SES.90 Possible explanations are that persons with low SES are 
often less engaged in favorable lifestyle choices91, like eating healthily92 or taking part in 
physical activity during leisure time.93 It has also been claimed that persons with low 
SES may have fewer social supports and networks.94 Taken together these factors are 
assumed to negatively affect health outcomes in patients with cardiovascular disease. 
Study V 
Study V is a systematic review and meta-analysis. The aim was to provide a summary 
estimate of the association between preoperative depression and long-term survival in 
adults who underwent CABG. The pooled results from the meta-analysis showed a 
significant association between preoperative depression and worse long-term survival 
following CABG. Depression was defined by different methods in the seven studies, 
because of this we performed separate analyses in patients with antidepressant use 
before CABG and in patients with self-assessed depression through questionnaires 
before CABG. In the analysis with depression based on questionnaires the HR was 1.47 
(95% CI 0.94 to 2.31) and in the group with antidepressant use as a proxy for 
depression the HR was 1.32 (95% CI 1.13 to 1.54). A sensitivity analysis was also 
performed to measure the influence of individual studies on the primary outcome we 
did a series of new meta-analyses, omitting one study at a time. The HR changed only 
slightly when removing the largest study by Stenman et al., HR: 1.40 (95%CI 1.16 to 
1.69). A meta-analysis facilitates objective evaluation and pooling of different study 
populations, and makes it possible to analyze large and diverse cohorts of patients and 
summarize the field of interest up to a certain time. This is the first meta-analysis 
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investigating the association between depression before CABG and long-term mortality. 
There are, however, existing systematic reviews and meta-analyses on depression and 
CVD. 23,24 The results from our meta-analysis are in line with prior findings.  
Strengths and Limitations 
The strengths of study I-IV in this thesis involve the nationwide, population-based, 
longitudinal, cohort design; the large study population; and the complete and accurate 
follow-up and survival ascertainment due to the high-quality national Swedish 
registers. The cohorts consisted of all CABG procedures in Sweden. This gives good 
external validity and we believe that our results could be applied in other countries, 
with similar level of health care.  
It is known that between 31% and 45 % of all patients with cardiac disease suffer from 
depression.21,95 In our study population only 11% had at least one dispensed 
prescription of antidepressants before CABG surgery. Due to the observational study 
design it was not possible to use any kind of depression measurement. It is therefore 
likely that patients with a depressive disorder were present in the non-exposed group. 
This is in epidemiological terms referred to as information bias, when incorrect 
information about the study participant is collected. In study I, II and IV, we most likely 
have information bias due to misclassification of exposure. The Swedish Prescribed 
Drug Register only contains information on prescriptions since July 2005. Therefore, 
there are undoubtedly patients in our study who had a dispensed prescription of 
antidepressants before that date, and underwent surgery between 2006 and 2008. Such 
patients would erroneously be classified as non-exposed in our study. It is also possible 
that patients in the exposed group were not suffering from depressive disorder, but 
some other condition requiring antidepressant medication for example SSRI treatment 
for obsessive-compulsive disorder. 
Because the design in study I-IV prevents strong conclusions about causation, we can 
only speculate on the explanations for our findings. For example, it is not possible to 
answer the question of whether it is depression in itself or treatment with 
antidepressants that contributes to worse survival 
Another limitation is the lack of information regarding compliance, dosage and duration 
of antidepressant use. We only know that the antidepressant medication has been 
dispensed and the date of dispensing but we can only assume that the patients actually 
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have taken the dispensed antidepressant medication. Medical adherence generally 
refers to both primary adherence and secondary adherence. Primary adherence is the 
rate at which patients collect their newly prescribed medication from pharmacies and 
secondary adherence is the correct intake of a prescribed medication.96,97 There can be 
several reasons to why patients do not pick up their prescribed medication. The overall 
adherence to antidepressants is known to be low.98,99 In Freccero´s et al., study they 
found that primary adherence to antidepressants prescribed at primary health care 
centers in Sweden was 85%.100 
Clinical implications 
Depression is a significant, independent risk marker in patients with CVD. Depression 
should be considered as important as other well-known risk factors like for example 
heart failure and chronic kidney disease in patients undergoing CABG. It can be difficult 
to detect depression in patients with CVD as symptoms in both conditions many times 
are the same. One way to detect depression is through systematic screening. In October 
2008 the American Heart Association (AHA) prevention Committee recommended that 
all coronary heart disease patients should be screened for depression using the 2-item 
Patient Health Questionnaire (PHQ-2) and that patients with a positive PHQ-2 screen 
would be followed up by using the 9-item PHQ-9 screen.95 The patients who screened 
positive on PHQ-9 would be given a treatment referral.101 In the US Preventive Services 
Task Force Recommendation Statement102 screening for depression is recommended in 
the general adult population as depression is among the leading causes of disability and 
the magnitude of harms of screening for depression in adults is small to none.102 This 
statement further stresses the importance of systematic screening for depression in 
patients with CVD. 
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Conclusions 
 
• Antidepressant use was associated with worse long-term survival after CABG.  
• Antidepressant use was also associated with an increased risk of 
rehospitalization for heart failure, myocardial infarction or stroke and a 
combination of rehospitalization or death.  
• Preoperative depression was not associated with lower use of guideline-
directed medications for secondary prevention of cardiovascular events.  
• Preoperative major depression was associated with worse long-term survival 
after CABG. 
• Preoperative major depression was also associated with an increased risk of 
the combined endpoint of death or rehospitalization for heart failure, 
myocardial infarction or stroke.  
• Preoperative antidepressant use was associated with worse long-term 
survival even after controlling for socioeconomic factors. 
• Depression was a significant risk marker for worse long-term survival 
following CABG in a systematic review and meta-analysis of 7 observational 
cohort studies. 
 
 
 
  47 
ACKNOWLEDGEMENTS 
I wish to express my sincere gratitude to everyone who has helped me to complete this 
thesis:  
Associate professor Ulrik Sartipy, my main supervisor, for making this journey 
extremely well directed, for being a master of epidemiology, statistics and 
computers, for your willingness to teach, for never being more than an email away, for 
always finding time when needed, for your constant good mood and all 
the discussions. Thank you!  
Associate professor Martin Holzmann, my co-supervisor, for 
your positive energy, for reading manuscripts and commenting within 24 hours and 
for throwing great parties!  
Professor Anders Franco-Cereceda, for always being encouraging, wise, generous and 
positive and for promoting the importance of clinical research.  
Head of the Department of Cardiothoracic surgery and Anesthesiology Ulf 
Lockowandt, for allowing me to take time off from my clinical work.  
Past and present head nurses Britt Persson Askling, Gunilla Barr and Cecilia 
Martin-Löf, for letting me take time off from my clinical duties even during tough 
times.  
All colleagues and friends at Thoraxkliniken, you have all been enormously 
supportive.  
Gabriella Engström, my mentor, for valuable talks via Skype. 
Tommy Bergkvist, for your fantastic math and statistics support (and Minecraft 
support).  
All my non-work friends, you are all extremely important to me and are always 
there when I need distraction from research and work.  
Gunilla & Rainer, my parents, and Urban my brother, for always being there. 
Lovisa & Gustav, mina fina, kloka, underbara barn. Jag älskar er över allt annat!!  
Jesper, my husband and solid rock. I love you!  
 
This work was supported by research grants from: The Swedish Heart- Lung 
Foundation, The Swedish Society of Medicine, The Mats Kleberg Foundation, The Capio 
Research Foundation and Karolinska Institutet Foundations and Funds. 
 
 48 
 
 
  49 
REFERENCES 
 
1. SWEDEHEART Annual report 2014 
http://www.ucr.uu.se/swedeheart/index.php/dokument-
sh/arsrapporter/doc_download/392-swedeheart-arsrapport-2014-english-
engelsk. Accessed 2016-04-15. 
2. Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish Web-system for 
enhancement and development of evidence-based care in heart disease 
evaluated according to recommended therapies (SWEDEHEART). Heart. 
2010;96(20):1617-1621. 
3. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1):55-
68. 
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive 
disorder: results from the National Comorbidity Survey Replication (NCS-R). 
JAMA. 2003;289(23):3095-3105. 
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 
2002 to 2030. PLoS Med. 2006;3(11):e442. 
6. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third 
universal definition of myocardial infarction. Glob Heart. 2012;7(4):275-295. 
7. White HD, Chew DP. Acute myocardial infarction. Lancet. 2008;372(9638):570-
584. 
8. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in 
women and men: insights from the INTERHEART study. Eur Heart J. 
2008;29(7):932-940. 
9. Leegaard M, Fagermoen MS. Patients' key experiences after coronary artery 
bypass grafting: a synthesis of qualitative studies. Scand J Caring Sci. 
2008;22(4):616-628. 
10. Goetz RH, Rohman M, Haller JD, Dee R, Rosenak SS. Internal mammary-coronary 
artery anastomosis. A nonsuture method employing tantalum rings. J Thorac 
Cardiovasc Surg. 1961;41:378-386. 
11. Buxton BF, Galvin SD. The history of arterial revascularization: from Kolesov to 
Tector and beyond. Ann Cardiothorac Surg. 2013;2(4):419-426. 
12. McKenzie LH, Simpson J, Stewart M. A systematic review of pre-operative 
predictors of post-operative depression and anxiety in individuals who have 
undergone coronary artery bypass graft surgery. Psychol Health Med. 
2010;15(1):74-93. 
13. SWEDEHEART Annual report 2015  
http://www.ucr.uu.se/swedeheart/index.php/component/docman/doc_downl
oad/462-swedeheart-2015. Accessed 2016-04-12. 
 50 
14. Johansson R, Carlbring P, Heedman A, Paxling B, Andersson G. Depression, 
anxiety and their comorbidity in the Swedish general population: point 
prevalence and the effect on health-related quality of life. PeerJ. 2013;1:e98. 
15. McManus D, Pipkin SS, Whooley MA. Screening for depression in patients with 
coronary heart disease (data from the Heart and Soul Study). Am J Cardiol. 
2005;96(8):1076-1081. 
16. Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical 
illnesses. Arch Intern Med. 2000;160(10):1522-1526. 
17. Moreno-Kustner B, Jones R, Svab I, et al. Suicidality in primary care patients who 
present with sadness and anhedonia: a prospective European study. BMC 
Psychiatry. 2016;16(1):94. 
18. Lesage AD, Boyer R, Grunberg F, et al. Suicide and mental disorders: a case-
control study of young men. Am J Psychiatry. 1994;151(7):1063-1068. 
19. The National Board of Health and Welfare 
http://www.socialstyrelsen.se/psykiskohalsa/sjalvmord. Accessed 2016-04-15. 
20. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial 
infarction. Impact on 6-month survival. JAMA. 1993;270(15):1819-1825. 
21. Celano CM, Huffman JC. Depression and cardiac disease: a review. Cardiol Rev. 
2011;19(3):130-142. 
22. Dhar AK, Barton DA. Depression and the Link with Cardiovascular Disease. Front 
Psychiatry. 2016;7:33. 
23. Nemeroff CB, Goldschmidt-Clermont PJ. Heartache and heartbreak--the link 
between depression and cardiovascular disease. Nat Rev Cardiol. 2012;9(9):526-
539. 
24. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. 
Depression and the risk for cardiovascular diseases: systematic review and meta 
analysis. Int J Geriatr Psychiatry. 2007;22(7):613-626. 
25. Reese RL, Freedland KE, Steinmeyer BC, Rich MW, Rackley JW, Carney RM. 
Depression and rehospitalization following acute myocardial infarction. Circ 
Cardiovasc Qual Outcomes. 2011;4(6):626-633. 
26. Dunkel A, Kendel F, Lehmkuhl E, et al. Predictors of preoperative depressive risk 
in patients undergoing coronary artery bypass graft surgery. Clin Res Cardiol. 
2009;98(10):643-650. 
27. Kessler RC. Epidemiology of women and depression. J Affect Disord. 
2003;74(1):5-13. 
28. Mitchell RH, Robertson E, Harvey PJ, et al. Sex differences in depression after 
coronary artery bypass graft surgery. Am Heart J. 2005;150(5):1017-1025. 
29. Kerr LK, Kerr LD, Jr. Screening tools for depression in primary care: the effects of 
culture, gender, and somatic symptoms on the detection of depression. West J 
Med. 2001;175(5):349-352. 
30. Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck 
Depression Inventory. A review. Psychopathology. 1998;31(3):160-168. 
  51 
31. Blumenthal JA, Lett HS, Babyak MA, et al. Depression as a risk factor for mortality 
after coronary artery bypass surgery. Lancet. 2003;362(9384):604-609. 
32. Connerney I, Sloan RP, Shapiro PA, Bagiella E, Seckman C. Depression is 
associated with increased mortality 10 years after coronary artery bypass 
surgery. Psychosom Med. 2010;72(9):874-881. 
33. Tully PJ, Baker RA, Knight JL. Anxiety and depression as risk factors for mortality 
after coronary artery bypass surgery. J Psychosom Res. 2008;64(3):285-290. 
34. Xiong GL, Jiang W, Clare R, et al. Prognosis of patients taking selective serotonin 
reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol. 
2006;98(1):42-47. 
35. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major 
depression. JAMA. 1990;264(12):1546-1549. 
36. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful 
life events and the onset of major depression. Am J Psychiatry. 1999;156(6):837-
841. 
37. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: 
moderation by a polymorphism in the 5-HTT gene. Science. 
2003;301(5631):386-389. 
38. Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a 
novel theory of depression. Mol Psychiatry. 2000;5(3):262-269. 
39. Elhwuegi AS. Central monoamines and their role in major depression. Prog 
Neuropsychopharmacol Biol Psychiatry. 2004;28(3):435-451. 
40. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 
2009;6(6):399-409. 
41. Gregg D, Goldschmidt-Clermont PJ. Cardiology patient page. Platelets and 
cardiovascular disease. Circulation. 2003;108(13):e88-90. 
42. Goldschmidt-Clermont PJ. Loss of bone marrow-derived vascular progenitor 
cells leads to inflammation and atherosclerosis. Am Heart J. 2003;146(4 
Suppl):S5-12. 
43. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of 
the tumor necrosis factor antagonist infliximab for treatment-resistant 
depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 
2013;70(1):31-41. 
44. Pikhart H, Hubacek JA, Kubinova R, et al. Depressive symptoms and levels of C-
reactive protein: a population-based study. Soc Psychiatry Psychiatr Epidemiol. 
2009;44(3):217-222. 
45. Raedler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin 
Psychiatry. 2011;24(6):519-525. 
46. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from 
the Third National Health and Nutrition Examination Survey. Arch Intern Med. 
2004;164(9):1010-1014. 
 52 
47. Bankier B, Barajas J, Martinez-Rumayor A, Januzzi JL. Association between major 
depressive disorder and C-reactive protein levels in stable coronary heart 
disease patients. J Psychosom Res. 2009;66(3):189-194. 
48. Lesperance F, Frasure-Smith N, Theroux P, Irwin M. The association between 
major depression and levels of soluble intercellular adhesion molecule 1, 
interleukin-6, and C-reactive protein in patients with recent acute coronary 
syndromes. Am J Psychiatry. 2004;161(2):271-277. 
49. Frasure-Smith N, Lesperance F, Irwin MR, Sauve C, Lesperance J, Theroux P. 
Depression, C-reactive protein and two-year major adverse cardiac events in 
men after acute coronary syndromes. Biol Psychiatry. 2007;62(4):302-308. 
50. Frasure-Smith N, Lesperance F, Irwin MR, Talajic M, Pollock BG. The 
relationships among heart rate variability, inflammatory markers and 
depression in coronary heart disease patients. Brain Behav Immun. 
2009;23(8):1140-1147. 
51. Schins A, Tulner D, Lousberg R, et al. Inflammatory markers in depressed post-
myocardial infarction patients. J Psychiatr Res. 2005;39(2):137-144. 
52. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is 
impaired in treated depression. Heart. 2002;88(5):521-523. 
53. Harris KF, Matthews KA, Sutton-Tyrrell K, Kuller LH. Associations between 
psychological traits and endothelial function in postmenopausal women. 
Psychosom Med. 2003;65(3):402-409. 
54. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired 
endothelial function in coronary heart disease patients with depressive 
symptomatology. J Am Coll Cardiol. 2005;46(4):656-659. 
55. Tiemeier H, van Dijck W, Hofman A, Witteman JC, Stijnen T, Breteler MM. 
Relationship between atherosclerosis and late-life depression: the Rotterdam 
Study. Arch Gen Psychiatry. 2004;61(4):369-376. 
56. Tomfohr LM, Martin TM, Miller GE. Symptoms of depression and impaired 
endothelial function in healthy adolescent women. J Behav Med. 2008;31(2):137-
143. 
57. Kleiger RE, Miller JP, Bigger JT, Jr., Moss AJ. Decreased heart rate variability and 
its association with increased mortality after acute myocardial infarction. Am J 
Cardiol. 1987;59(4):256-262. 
58. Bassett D. A literature review of heart rate variability in depressive and bipolar 
disorders. Aust N Z J Psychiatry. 2015. 
59. Emilsson L, Lindahl B, Koster M, Lambe M, Ludvigsson JF. Review of 103 Swedish 
Healthcare Quality Registries. J Intern Med. 2015;277(1):94-136. 
60. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the 
Swedish national inpatient register. BMC Public Health. 2011;11:450. 
61. Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart 
failure in a hospital discharge register. Eur J Heart Fail. 2005;7(5):787-791. 
62. Dödsorsaksregistret.  http://www.socialstyrelsen.se/statistics. Accessed 2016-
04-12. 
  53 
63. Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total 
population and their use in medical research. Eur J Epidemiol. 2016;31(2):125-
136. 
64. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug 
Register--opportunities for pharmacoepidemiological research and experience 
from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726-735. 
65. Statistics Sweden LISA-database  http://www.scb.se/en_/Services/Guidance-
for-researchers-and-universities/SCB-Data/Longitudinal-integration-database-
for-health-insurance-and-labour-market-studies-LISA-by-Swedish-acronym/. 
Accessed 2016-04-12. 
66. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish 
personal identity number: possibilities and pitfalls in healthcare and medical 
research. Eur J Epidemiol. 2009;24(11):659-667. 
67. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
analyses. BMJ. 2003;327(7414):557-560. 
68. Li P, Stuart EA, Allison DB. Multiple Imputation: A Flexible Tool for Handling 
Missing Data. JAMA. 2015;314(18):1966-1967. 
69. White IR, Royston P, Wood AM. Multiple imputation using chained equations: 
Issues and guidance for practice. Stat Med. 2011;30(4):377-399. 
70. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat 
Med. 2009;28(15):1982-1998. 
71. Rothman KJ. Epidemiology: an introduction. New York: Oxford University Press, 
Inc; 2002. 
72. Rothman KJ, Greenland, Sander, Lash, Timothy L. Modern Epidemiology. 
Philadelphia: Lippincott Williams & Wilkins; 2008. 
73. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective 
serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 
2004;91(1):119-128. 
74. Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. 
Relationship of serotonergic antidepressants and need for blood transfusion in 
orthopedic surgical patients. Arch Intern Med. 2003;163(19):2354-2358. 
75. Kim DH, Daskalakis C, Whellan DJ, et al. Safety of selective serotonin reuptake 
inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol. 
2009;103(10):1391-1395. 
76. Andreasen JJ, Riis A, Hjortdal VE, Jorgensen J, Sorensen HT, Johnsen SP. Effect of 
selective serotonin reuptake inhibitors on requirement for allogeneic red blood 
cell transfusion following coronary artery bypass surgery. Am J Cardiovasc Drugs. 
2006;6(4):243-250. 
77. Tully PJ, Cardinal T, Bennetts JS, Baker RA. Selective serotonin reuptake 
inhibitors, venlafaxine and duloxetine are associated with in hospital morbidity 
but not bleeding or late mortality after coronary artery bypass graft surgery. 
Heart Lung Circ. 2012;21(4):206-214. 
 54 
78. Li Y, Glance LG, Cai X, Mukamel DB. Are patients with coexisting mental 
disorders more likely to receive CABG surgery from low-quality cardiac 
surgeons? The experience in New York State. Med Care. 2007;45(7):587-593. 
79. Kronish IM, Rieckmann N, Halm EA, et al. Persistent depression affects 
adherence to secondary prevention behaviors after acute coronary syndromes. J 
Gen Intern Med. 2006;21(11):1178-1183. 
80. Horne D, Kehler S, Kaoukis G, et al. Depression before and after cardiac surgery: 
do all patients respond the same? J Thorac Cardiovasc Surg. 2013;145(5):1400-
1406. 
81. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for 
mortality in patients with coronary heart disease: a meta-analysis. Psychosom 
Med. 2004;66(6):802-813. 
82. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety 
improvement on adherence to medication and health behaviors in recently 
hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266-1271. 
83. Martin LA, Neighbors HW, Griffith DM. The experience of symptoms of 
depression in men vs women: analysis of the National Comorbidity Survey 
Replication. JAMA Psychiatry. 2013;70(10):1100-1106. 
84. Gale CR, Batty GD, Osborn DP, Tynelius P, Rasmussen F. Mental disorders across 
the adult life course and future coronary heart disease: evidence for general 
susceptibility. Circulation. 2014;129(2):186-193. 
85. Green CA, Pope CR. Depressive symptoms, health promotion, and health risk 
behaviors. Am J Health Promot. 2000;15(1):29-34. 
86. Stephens T. Physical activity and mental health in the United States and Canada: 
evidence from four population surveys. Prev Med. 1988;17(1):35-47. 
87. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for 
noncompliance with medical treatment: meta-analysis of the effects of anxiety 
and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-
2107. 
88. Poole L, Leigh E, Kidd T, Ronaldson A, Jahangiri M, Steptoe A. The combined 
association of depression and socioeconomic status with length of post-
operative hospital stay following coronary artery bypass graft surgery: data from 
a prospective cohort study. J Psychosom Res. 2014;76(1):34-40. 
89. Andersen KK, Dalton SO, Steding-Jessen M, Olsen TS. Socioeconomic position and 
survival after stroke in Denmark 2003 to 2012: nationwide hospital-based study. 
Stroke. 2014;45(12):3556-3560. 
90. Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 
22 European countries. N Engl J Med. 2008;358(23):2468-2481. 
91. Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with 
health behaviors and mortality. JAMA. 2010;303(12):1159-1166. 
92. Darmon N, Drewnowski A. Does social class predict diet quality? Am J Clin Nutr. 
2008;87(5):1107-1117. 
  55 
93. Beenackers MA, Kamphuis CB, Giskes K, et al. Socioeconomic inequalities in 
occupational, leisure-time, and transport related physical activity among 
European adults: a systematic review. Int J Behav Nutr Phys Act. 2012;9:116. 
94. Hunt J, Marshall AL, Jenkins D. Exploring the meaning of, the barriers to and 
potential strategies for promoting physical activity among urban Indigenous 
Australians. Health Promot J Austr. 2008;19(2):102-108. 
95. Lichtman JH, Bigger JT, Jr., Blumenthal JA, et al. Depression and coronary heart 
disease: recommendations for screening, referral, and treatment: a science 
advisory from the American Heart Association Prevention Committee of the 
Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on 
Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care 
and Outcomes Research: endorsed by the American Psychiatric Association. 
Circulation. 2008;118(17):1768-1775. 
96. Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic disadvantage 
and primary non-adherence with medication in Sweden. Int J Qual Health Care. 
2007;19(3):134-140. 
97. Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with primary 
non-adherence to medications for hypertension, diabetes, and lipid disorders. J 
Gen Intern Med. 2012;27(1):57-64. 
98. Woolley SB, Fredman L, Goethe JW, Lincoln AK, Heeren T. Hospital patients' 
perceptions during treatment and early discontinuation of serotonin selective 
reuptake inhibitor antidepressants. J Clin Psychopharmacol. 2010;30(6):716-719. 
99. Ereshefsky L, Saragoussi D, Despiegel N, Hansen K, Francois C, Maman K. The 6-
month persistence on SSRIs and associated economic burden. J Med Econ. 
2010;13(3):527-536. 
100. Freccero C, Sundquist K, Sundquist J, Ji J. Primary adherence to antidepressant 
prescriptions in primary health care: a population-based study in Sweden. Scand 
J Prim Health Care. 2016;34(1):83-88. 
101. Sowden G, Mastromauro CA, Januzzi JL, Fricchione GL, Huffman JC. Detection of 
depression in cardiac inpatients: feasibility and results of systematic screening. 
Am Heart J. 2010;159(5):780-787. 
102. Siu AL, Bibbins-Domingo K, Grossman DC, et al. Screening for Depression in 
Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 
2016;315(4):380-387. 
 
